It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Psoriasis is the most common skin disease in adults. Current experimental and clinical evidences suggested the infiltrating immune cells could target local skin cells and thus induce psoriatic phenotype. However, recent studies indicated the existence of a potential feedback signaling loop from local resident skin cells to infiltrating immune cells. Here, we deconstructed the full-thickness human skins of both healthy donors and patients with psoriasis vulgaris at single cell transcriptional level, and further built a neural-network classifier to evaluate the evolutional conservation of skin cell types between mouse and human. Last, we systematically evaluated the intrinsic and intercellular molecular alterations of each cell type between healthy and psoriatic skin. Cross-checking with psoriasis susceptibility gene loci, cell-type based differential expression, and ligand-receptor communication revealed that the resident psoriatic skin cells including mesenchymal and epidermis cell types, which specifically harbored the target genes of psoriasis susceptibility loci, intensively evoked the expression of major histocompatibility complex (MHC) genes, upregulated interferon (INF), tumor necrosis factor (TNF) signalling and increased cytokine gene expression for primarily aiming the neighboring dendritic cells in psoriasis. The comprehensive exploration and pathological observation of psoriasis patient biopsies proposed an uncovered immunoregulatory axis from skin local resident cells to immune cells, thus provided a novel insight for psoriasis treatment. In addition, we published a user-friendly website to exhibit the transcriptional change of each cell type between healthy and psoriatic human skin.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 The Second Affiliated Hospital of Harbin Medical University, Department of Dermatology, Harbin, China (GRID:grid.412463.6) (ISNI:0000 0004 1762 6325); University of Helsinki, Institute of Biotechnology, HILIFE Unit, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
2 Peking University First Hospital, Department of Dermatology, Beijing, China (GRID:grid.411472.5) (ISNI:0000 0004 1764 1621)
3 The Second Affiliated Hospital of Harbin Medical University, Department of Dermatology, Harbin, China (GRID:grid.412463.6) (ISNI:0000 0004 1762 6325)
4 The Second Affiliated Hospital of Harbin Medical University, Department of Oncology, Harbin, China (GRID:grid.412463.6) (ISNI:0000 0004 1762 6325)
5 University of Helsinki, Institute of Biotechnology, HILIFE Unit, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
6 Division of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Solna, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)